Management and Long-term Outcomes of Adults With Medulloblastoma
- 19 September 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (12) , E1256-E1271
Abstract
OBJECTIVE: Medulloblastomas are embryonal tumors predominantly affecting children. Recognition of molecularly defined subgroups has advanced management. Factors influencing the management and prognosis of adult patients with medulloblastoma remains poorly understood. METHODS: We examined management, prognostic factors, and when possible molecular subgroup differences (subset) in adult medulloblastoma patients (>18 years) from our center (specialty Neuro-Oncology clinic within a large academic practice) diagnosed between 1992-2020. Molecular subtyping corresponding to the 2021 WHO Classification was performed. Kaplan-Meier estimates (with Log-rank test) were performed for univariate survival analysis with cox regression used for multivariate analyses. RESULTS: We included 76 adult medulloblastoma patients (62% male), with a median age of 32 years at diagnosis (range: 18-66), and median follow-up of 7.7 years (range: 0.6-27). A subset of 58 patients had molecular subgroup characterization – 37 SHH-activated, 12 non-WNT/non-SHH, and 9 WNT-activated. 67% underwent gross total resection, 75% received chemotherapy at diagnosis, and 97% received craniospinal irradiation with boost. Median overall survival (OS) for the whole cohort was 14.8 years. The 2, 5, and 10-year OS was 93% (95% CI: 88-99%), 86% (78-94%), and 64% (53-78%), respectively. Survival was longer for younger patients (≥30 years old: 9.9 years; 15.4 years; Log-rank p<0.001). There was no survival difference by molecular subgroup or extent of resection. Only age at diagnosis remained significant in multivariate survival analyses. CONCLUSION: We report one of the largest retrospective cohorts in adult medulloblastoma patients with molecular subtyping. Survival and molecular subgroup frequencies were similar to prior reports. Survival was better for adult patients younger than 30 years at diagnosis and was not significantly different by molecular subgroup or management characteristics (extent of resection, RT characteristics, or chemotherapy timing or regimen).Keywords
This publication has 43 references indexed in Scilit:
- Médulloblastomes de l’adulte : étude rétrospective portant sur 21 patientsCancer/Radiothérapie, 2016
- Long-term Outcomes and Role of Chemotherapy in Adults With Newly Diagnosed MedulloblastomaAmerican Journal of Clinical Oncology, 2014
- The role of radiotherapy in adult medulloblastoma: long-term single-institution experience and a review of the literatureJournal of Neuro-Oncology, 2011
- Adult Medulloblastoma Comprises Three Major Molecular VariantsJournal of Clinical Oncology, 2011
- Characteristics and outcomes of medulloblastoma in adultsPediatric Blood & Cancer, 2008
- Adult medulloblastoma: Clinical profile and treatment results of 18 patientsJournal of Clinical Neuroscience, 2008
- Long‐term results of a prospective study on the treatment of medulloblastoma in adultsCancer, 2007
- Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments?Expert Review of Anticancer Therapy, 2003
- Adult Medulloblastoma: Prognostic Factors and Patterns of RelapseNeurosurgery, 2000
- Adult medulloblastoma.Journal of Neurology, Neurosurgery & Psychiatry, 1986